ABVX vs PFE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
PFE is the larger of the two ($165.41B market cap): the incumbent the market prices for continued execution (9.88x forward earnings, beta 0.30). ABVX is the smaller challenger ($7.95B), priced similarly on forward earnings (-23.67x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ABVX vs PFE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABVX | PFE | What it tells you |
|---|---|---|---|
| Market cap | $7.95B | $165.41B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -23.67 | 9.88 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | -0.33 | 0.30 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 27% of range | 69% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 17.61 | 1.86 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ABVX and PFE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Abivax SA (ABVX) do?
Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the registrational Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo; maintenance results came on June 1, 2026 and Part 2 results with the maintenance safety database on June 29. A pre-NDA interaction with the FDA followed on July 30, management plans to file the U.S. new drug application at the end of 2026, and a Phase 2b Crohn's disease readout (ENHANCE-CD) is expected around mid-2027.
What does Pfizer (PFE) do?
Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.
ABVX vs PFE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
- PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.
ABVX or PFE: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and PFE guides.
ABVX vs PFE: the full fundamentals
ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding late-stage trials and launch preparation rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market, and after the 2026 pullback the roughly $7.75B market cap sits well below the average analyst target of about $164 per ADR. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.
PFE. Pfizer trades at about 10x forward earnings and a dividend yield near 5.8%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges rather than weak operations. Even after a 17.5% gain in 2026 the shares sit right around the 26 analysts' mean target of about $29, so the valuation now balances substantial cash generation against flat-to-lower consensus earnings.
Headline figures (approximate, October 2026): ABVX shows market cap ~$7.75B, share price (oct 16, 2026) ~$89 (52-week range ~$70-149), revenue (ttm) ~negligible (~$4.7M, pre-commercial), net loss (h1 2026) ~EUR 166M; PFE shows revenue (ttm) ~$63.7 billion (Q2 2026 +~2.6% YoY), operating margin ~28%, net income (ttm, gaap) ~$4.3 billion, q2 2026 adjusted eps ~$0.77 vs ~$0.68 consensus.
The bottom line: ABVX vs PFE
ABVX and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and PFE exposure against your real portfolio. It is not an investment adviser.
Wondering how ABVX or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Abivax SA
Ask Walnut's AI anything about ABVX and see how it fits what you own.
FAQ
What is the difference between ABVX and PFE?
+
Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABVX or PFE the better stock?
+
Neither is universally better. PFE is the larger incumbent; ABVX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABVX or PFE?
+
On forward P/E (as of November 2026), ABVX trades at -23.67x and PFE at 9.88x, so ABVX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABVX and PFE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABVX vs PFE?
+
ABVX: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Malignancy signals at the 50 mg dose have been a focal regulatory question, even though integrated safety data reported rates in line with background disease incidence. The ulcerative colitis market is crowded with established therapies such as Rinvoq, Skyrizi, Zeposia, and Entyvio, so commercial success is not guaranteed even after approval. The company generates negligible revenue and large net losses (about EUR 401M over the trailing twelve months, with spending rising as launch preparation begins), and repeated equity raises have diluted shareholders. The roughly 34% fall in the ADR over three months to October 2026 shows how volatile sentiment remains even after positive data. Approval, launch execution, a leadership transition in the medical function, and any partnership or acquisition outcome all remain uncertain. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of October 2026 has revenue slipping to about $62.2 billion in 2026 and $59.9 billion in 2027, with EPS of roughly $2.96 and $2.89, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.5 billion against $11.7 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout above 200% on trailing GAAP EPS), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABVX or PFE; figures are approximate and dated (as of November 2026). Verify current data before investing.